title: Electrical sources of P300 event-related brain potentials revealed by low resolution electromagnetic tomography. 2. Effects of nootropic therapy in age-associated memory impairment.
abstract: In a double-blind, placebo-controlled study the effects of Actovegin on frontal and parietal electrical P300 sources revealed by low resolution electromagnetic tomography (LORETA) were studied in age-associated memory impairment (AAMI) patients. Actovegin is a protein-free metabolically active hemoderivative improving oxygen and glucose utilization. Each patient had, in randomized order, a treatment of 2 weeks with 250 ml 20% Actovegin and 250 ml placebo daily. Auditory ERPs were recorded before and 5 h after drug administration on day 1 (acute effect) and on day 15 (subacute and superimposed effect). Compared to age- and sex-matched normal controls, AAMI patients showed a trend towards P300 latency prolongation and a significantly reduced P300 global field power (GFP). Maximal LORETA source strength did not differ from controls. After Actovegin parietal P300 scalp amplitudes increased, while frontal and temporal amplitudes decreased as compared to placebo. This increase in hilliness, measured by the GFP, was significant. Moreover, the parietal P300 source strength increased after acute, subacute and superimposed infusion of Actovegin as compared to placebo. This may reflect improved availability of cognitive processing resources in the parietal cortex, an area that on the one hand plays an important role in fundamental aspects of attention and on the other hand has been found to be functionally impaired in dementia.
authors.affiliation: Department of Psychiatry, University of Vienna, Austria.
authors.forename: P
authors.initials: P
authors.lastname: Anderer
authors.forename: B
authors.initials: B
authors.lastname: Saletu
authors.forename: H V
authors.initials: HV
authors.lastname: Semlitsch
authors.forename: R D
authors.initials: RD
authors.lastname: Pascual-Marqui
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000375:Aging / Q000523:psychology; D001921:Brain / Q000033:anatomy & histology* / Q000502:physiology*; D000697:Central Nervous System Stimulants / Q000627:therapeutic use*; D018592:Cross-Over Studies; D004311:Double-Blind Method; D018913:Event-Related Potentials, P300 / Q000187:drug effects / Q000502:physiology*; D005072:Evoked Potentials, Auditory / Q000187:drug effects / Q000502:physiology*; D005260:Female; D006418:Heme / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D015225:Magnetoencephalography; D008297:Male; D008569:Memory Disorders / Q000188:drug therapy* / Q000523:psychology; D008875:Middle Aged
chemical_list: D000697:Central Nervous System Stimulants; D006418:Heme; C015646:Actovegin